Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Calls Off Plan To Acquire Crucell

This article was originally published in The Pink Sheet Daily

Executive Summary

Question remains whether Pfizer or another pharma will make play for Dutch vaccine-focused firm.
Advertisement

Related Content

Deals Of The Week: J&J/Crucell, Merck/Beijing Genomics Institute …
Deals Of The Week: J&J/Crucell, Merck/Beijing Genomics Institute …
Johnson & Johnson Plans Move Into Vaccines With Bid For Remainder Of Crucell
J&J Buys $440 Mil. Stake In Crucell; Will Collaborate On Universal Flu Vaccine
Emilio Emini Is The Key To Wyeth Vaccines
Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?
Wyeth Moves To Broaden Prevnar: Prepares Offer For Crucell
Wyeth Moves To Broaden Prevnar: Prepares Offer For Crucell
Pfizer Strengthens Therapeutic Vaccine Position With Coley Purchase
How Wyeth Plans to Make Prevnar a $3 Billion Vaccine

Topics

Advertisement
UsernamePublicRestriction

Register

PS068514

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel